Vyleesi Satisfaction Trends Over Time: What Real Users Report About Bremelanotide

What RECONNECT Showed About Bremelanotide Efficacy

The RECONNECT program, comprising two identical Phase 3 randomized controlled trials, remains the primary evidence base for Vyleesi. Published in Obstetrics & Gynecology in 2019, these trials enrolled 1,247 premenopausal women with generalized acquired HSDD and followed them for 24 weeks 1.

Co-Primary Endpoints

Both trials met their co-primary endpoints. Women receiving bremelanotide 1.75 mg showed a statistically significant increase in the number of satisfying sexual events (SSEs) compared to placebo. The FSFI desire domain score improved by approximately 0.5 points more than placebo, a difference that reached statistical significance (P<0.05) 1.

Distress Scores Declined Meaningfully

The Female Sexual Distress Scale, Desire/Arousal/Orgasm (FSDS-DAO) score dropped significantly in the bremelanotide arm. This matters because HSDD is defined not just by low desire but by the personal distress it causes. The reduction in distress was consistent across both studies, and the effect was present by week 4 of treatment 1.

The Open-Label Extension Signal

An open-label extension allowed women to continue bremelanotide for up to 12 months. Approximately 55% of women who entered the extension completed it. Those who remained on treatment showed sustained improvements in desire and distress metrics, though this population is inherently self-selected: women who experienced benefit continued, while those who did not had already dropped out 1.

How Satisfaction Shifts During the First 90 Days

The trajectory of Vyleesi satisfaction follows a predictable pattern that clinicians and patients should anticipate. The first three months represent a critical window where most users either become long-term responders or discontinue.

Weeks 1 Through 4: The Nausea Gauntlet

Nausea affected 40.0% of bremelanotide-treated women in RECONNECT versus 1.3% on placebo 1. User forums consistently describe this as the make-or-break period. Online reports from communities including Reddit and Drugs.com describe first-dose nausea lasting 2 to 6 hours, sometimes accompanied by flushing and headache. A subset of users report nausea severe enough to overshadow any benefit from increased desire.

The FDA label recommends an antiemetic (such as ondansetron) if nausea is bothersome. Women who use prophylactic antiemetics during the first several doses report higher persistence rates in observational accounts, though no randomized data confirms this strategy.

Weeks 4 Through 8: Nausea Adaptation

For women who persist through early doses, nausea tends to diminish. The RECONNECT data showed that nausea severity and frequency decreased with repeated dosing 1. Online user reports align with this pattern. Multiple accounts describe the third or fourth injection as the turning point where nausea became manageable or disappeared entirely.

Weeks 8 Through 12: Emerging Responder Clarity

By the end of month three, the picture clarifies. Women who tolerated the initial side effects and noticed increased desire or arousal tend to remain committed to treatment. Those who experienced no perceptible change in desire typically discontinue. This mirrors the RECONNECT open-label extension attrition curve, where most dropouts occurred within the first 8 to 12 weeks.

What Real Users Report on Forums and Review Platforms

Online reviews of Vyleesi paint a strikingly bimodal picture. The drug rarely receives middling ratings. Users tend to cluster at the extremes.

Positive Responder Themes

Women who report benefit describe the experience in remarkably consistent terms across platforms. Increased mental interest in sexual activity is the most frequently cited change, often described as "thinking about sex again" or noticing attraction in ways that had been absent for months or years. Some women report that the medication does not create artificial arousal but instead removes a mental block.

Physical arousal changes are the second most reported benefit. Users describe improved lubrication and sensitivity, effects consistent with bremelanotide's melanocortin receptor agonist mechanism, which acts centrally on the hypothalamus rather than peripherally on genital tissue 2.

Negative Responder Themes

The most consistent complaint is nausea that does not resolve. A smaller but vocal group reports that the drug produced physical arousal without accompanying psychological desire, an experience described as uncomfortable rather than therapeutic. Injection site reactions, darkening of the gums or skin (hyperpigmentation), and headache round out the negative reports.

The Selection Bias Problem

Every online review sample is self-selected. Women who feel strongly, either positively or negatively, are more likely to post. Those in the middle, who experienced modest benefit with tolerable side effects, are underrepresented. The Drugs.com review base for Vyleesi remains small (typically under 100 ratings for any given period), making percentage-based conclusions unreliable. Reddit threads in communities like r/HSDD and r/WomensHealth contain individual narratives rather than aggregate data. These accounts are valuable for understanding the range of experiences but cannot substitute for controlled trial evidence.

Long-Term Satisfaction Beyond 6 Months

Limited controlled data exists beyond the 24-week RECONNECT endpoint. The open-label extension provides the best available long-term signal, supplemented by real-world persistence data and user reports.

12-Month Open-Label Data

Women who completed the full 12-month extension maintained the desire and distress improvements observed during the randomized phase. The mean number of SSEs per month remained elevated above pre-treatment baseline. No new safety signals emerged with prolonged use 1.

Persistence Rates in Practice

Real-world persistence with Vyleesi appears lower than trial continuation rates suggest. Cost is a primary driver: without insurance coverage, a four-dose carton runs approximately $900 to $1,000. The AMAG Pharmaceuticals patient assistance program (now under Cosette Pharmaceuticals after the 2023 acquisition) reduces out-of-pocket cost for eligible patients, but coverage through commercial insurance remains inconsistent.

Does Efficacy Wane?

A common question on user forums is whether Vyleesi "stops working" over time. The open-label extension data did not show tachyphylaxis (diminishing response with continued use) at 12 months 1. User reports are mixed. Some long-term users describe consistent benefit at 12 to 18 months. Others describe a subjective decrease in effect, though it is difficult to separate true pharmacological tolerance from shifting expectations or relationship dynamics.

Nausea Management Strategies That Affect Satisfaction

Nausea is the single largest determinant of whether a woman remains on Vyleesi. Clinical strategies to manage it directly affect satisfaction trends.

Prophylactic Antiemetics

Ondansetron 4 mg taken 30 minutes before the bremelanotide injection is the most commonly described approach in prescriber forums and patient accounts. The 2019 Endocrine Society clinical practice guidelines for female sexual dysfunction note that managing side effects proactively improves treatment adherence across pharmacotherapies for HSDD 3.

Dose Timing Optimization

The FDA label recommends injection at least 45 minutes before anticipated sexual activity. User reports suggest that injecting 60 to 90 minutes before activity, rather than the minimum 45, allows both the peak effect and the nausea window to stabilize. Injecting on an empty stomach worsens nausea in most accounts; a light meal 1 to 2 hours before injection is a commonly reported mitigation.

Injection Technique

Subcutaneous injection in the abdomen (versus the thigh) is associated with fewer reports of injection site reactions in user communities. The auto-injector design simplifies administration, but some women report switching to manual syringes for better control over injection speed, which they describe as reducing post-injection discomfort.

How Vyleesi Satisfaction Compares to Flibanserin

Women researching HSDD treatment often weigh Vyleesi against flibanserin (Addyi), the only other FDA-approved pharmacotherapy for premenopausal HSDD. Satisfaction trends differ meaningfully between the two.

Onset and Dosing Model

Flibanserin requires daily oral dosing for 4 to 8 weeks before benefit emerges 4. Vyleesi is used as needed, with effects beginning within a single dose. Women who want on-demand control tend to prefer Vyleesi. Women who prefer not to inject and are willing to wait for gradual onset may prefer flibanserin.

Side Effect Profiles Diverge

Flibanserin's primary side effects are dizziness, somnolence, and fatigue, with a black-box warning against alcohol use. Vyleesi's primary side effect is nausea, with no alcohol restriction. Forum discussions frequently describe women trying one medication, discontinuing due to side effects, and switching to the other. The "Vyleesi refugee" and "Addyi refugee" patterns are both common in online HSDD communities.

Head-to-Head Satisfaction Data

No randomized head-to-head trial comparing Vyleesi and flibanserin has been published. A 2020 network meta-analysis in The Journal of Sexual Medicine found that both drugs produced small but statistically significant improvements over placebo, with overlapping confidence intervals for efficacy 5. Patient preference appears driven more by side effect tolerance and dosing preference than by differential efficacy.

Factors That Predict Higher Satisfaction

Not every woman with HSDD responds to Vyleesi. Identifying likely responders before prescribing improves both satisfaction rates and appropriate resource allocation.

Acquired vs Lifelong HSDD

The RECONNECT trials enrolled only women with acquired generalized HSDD, meaning desire was previously normal and then declined. The FDA indication reflects this. Women with lifelong low desire were not studied, and user reports from this group are sparse and inconsistent. Clinicians who prescribe within the studied population report better outcomes.

Relationship Context

HSDD diagnosis requires that low desire is not better explained by relationship distress, psychiatric illness, or medication effects. Women who identify a clear temporal change in desire unrelated to relationship quality tend to report better results with Vyleesi. Forum accounts from women whose low desire coincided with relationship conflict are more likely to describe the medication as ineffective.

Realistic Expectations

The RECONNECT trial showed a mean increase of approximately 0.5 SSEs per month over placebo 1. That is a real but modest effect. Women who expected a dramatic transformation report lower satisfaction than those who understood the likely magnitude of change. The Endocrine Society guidelines emphasize shared decision-making and realistic goal-setting as components of HSDD management 3.

Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT trials, has stated: "The goal of treatment is not to create desire where none exists, but to remove the neurobiological barriers that are suppressing a woman's normal sexual response" 1.

The Cost-Satisfaction Relationship

Cost is inseparable from satisfaction for an as-needed medication with variable insurance coverage.

Insurance Coverage Field

Coverage for Vyleesi varies widely. Some commercial plans cover it with prior authorization and a documented HSDD diagnosis. Medicare does not cover Vyleesi, as the indication is limited to premenopausal women. Medicaid coverage varies by state. The prior authorization process typically requires documentation of failed non-pharmacological interventions (counseling, relationship therapy) and confirmation of the HSDD diagnosis by a specialist.

Out-of-Pocket Impact on Dosing Behavior

At roughly $225 to $250 per dose without insurance, women report rationing doses for "special occasions" rather than using them as needed per the label. This rationing behavior may artificially lower perceived efficacy: if a woman uses Vyleesi only 1 to 2 times per month instead of the studied frequency, the cumulative benefit is harder to assess. The FDA label permits up to 8 doses per month, and trial participants used the medication significantly more often than real-world accounts suggest.

Manufacturer Support Programs

Cosette Pharmaceuticals offers a copay assistance program that reduces the per-dose cost for commercially insured patients. Uninsured patients may qualify for patient assistance programs that provide the medication at reduced or no cost. Prescribers report that patients enrolled in these programs show higher persistence rates, consistent with the straightforward conclusion that lower cost leads to more consistent use and better satisfaction outcomes.

Safety Considerations That Shape Long-Term Use

Two safety signals from the RECONNECT program warrant ongoing attention for long-term users.

Blood Pressure Effects

Bremelanotide caused transient increases in systolic blood pressure (mean increase of approximately 3 mmHg) and decreases in heart rate shortly after injection 1. These changes resolved within 12 hours. The FDA label contraindicates Vyleesi in women with uncontrolled hypertension or known cardiovascular disease. The blood pressure effect has not been reported as clinically problematic in user forums, likely because the studied population excluded women with cardiovascular risk factors.

Focal Hyperpigmentation

Approximately 1% of women in RECONNECT developed darkening of the gums, face, or breasts 1. This effect is related to bremelanotide's melanocortin receptor activity. The hyperpigmentation was generally mild and reversible after discontinuation, but it is one of the more distinctive side effects that appears in user reports, sometimes causing concern disproportionate to its clinical significance.

The American College of Obstetricians and Gynecologists (ACOG) recommends that clinicians discuss both the benefits and limitations of pharmacotherapy for HSDD, including realistic efficacy expectations and common side effects, before initiating treatment 6.